Loss-of-heterozygosity as a biomarker for poor outcomes in endometrial cancer 

Felix Blanc-Durand, MD, Institut Gustave Roussy, Villejuif, France, discusses recent findings on the molecular subtypes in endometrial cancer. One subtype is characterized by high copy number alterations and ubiquitous TP53 mutations, resembling high-grade serous ovarian cancer. This led to the hypothesis that loss of heterozygosity (LOH) and homologous recombination deficiency (HRD) might be prevalent in these cancers. Using data from endometrial cancer patients who underwent large panel sequencing, including whole genome LOH assessment, it was found that a significant subset of TP53-mutated cancers exhibited high LOH. Specifically, around 20% of TP53-mutated endometrial cancers had high LOH, suggesting deficient homologous repair mechanisms. This subset could potentially benefit from PARP inhibitors, although further research is needed to confirm these findings. This interview took place at the ESMO Gynaecological Cancers Congress 2024 in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.